Cefozopran Dihydrochloride (CAS 113359-04-9 (HCl salt))

Cefozopran dihydrochloride is a fourth-generation cephalosporin antibiotic widely used in research to investigate bacterial cell wall synthesis inhibition mechanisms. It operates by binding to and inhibiting penicillin-binding proteins (PBPs), essential enzymes in the peptidoglycan cross-linking process within the bacterial cell wall. This disruption results in weakened cell walls and subsequent bacterial cell lysis. Cefozopran dihydrochloride is particularly valuable in studying the activity spectrum against Gram-positive and Gram-negative bacteria, including strains resistant to earlier cephalosporins. Research applications focus on understanding its high affinity for multiple PBPs, contributing to its broad-spectrum activity and resistance to beta-lactamases, enzymes that degrade beta-lactam antibiotics. Advanced studies employ cefozopran dihydrochloride to explore bacterial resistance mechanisms, structural modifications to enhance its antibacterial properties, and the development of new cephalosporin derivatives. It also serves as a model compound in pharmacokinetic and pharmacodynamic studies to assess the efficacy of cephalosporins in various bacterial infections. Researchers utilize techniques like X-ray crystallography and NMR spectroscopy to explain the molecular interactions between cefozopran dihydrochloride and its targets, providing insights into its potent antibacterial activity and guiding the design of novel antimicrobial agents. This compound is crucial for advancing the understanding of bacterial resistance and the development of next-generation antibiotics.